Reporting time toxicity in prospective cancer clinical trials: A scoping review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Time toxicity is rarely reported in cancer studies, lacking standard definitions and metrics. More research is needed to establish best practices for measuring and reporting time toxicity in oncology.
Area Of Science
- Oncology
- Clinical Trials
- Health Services Research
Background
- Time toxicity, defined as time spent receiving cancer care, is a critical patient-reported outcome.
- Understanding and quantifying time toxicity is essential for improving patient experience and optimizing cancer treatment delivery.
Purpose Of The Study
- To systematically review the measurement and reporting of time toxicity in prospective oncologic studies.
- To identify current methodologies and definitions used for assessing time toxicity in cancer clinical trials.
Main Methods
- A comprehensive literature search was conducted across PubMed, Scopus, and Embase for studies published between 1984 and 2023.
- Included studies were prospective or randomized controlled trials (RCTs) that reported time toxicity as an outcome.
- Evaluated studies for their definitions, metrics, and reporting of time toxicity.
Main Results
- Ten studies met the inclusion criteria, encompassing surgery, systemic therapies, and palliative care interventions.
- Reporting of time toxicity was inconsistent, with varied metrics such as 'days alive and out of hospital' and 'time spent at home'.
- Secondary analyses of RCTs demonstrated more comprehensive metrics, including both inpatient and ambulatory care time.
Conclusions
- Time toxicity is infrequently and inconsistently reported in oncologic clinical trials.
- There is a lack of standardized definitions, metrics, and methodologies for measuring time toxicity.
- Further research is required to develop and implement best practices for reporting time toxicity to alleviate patient burden.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...